DexCom, Inc. (DXCM) Given Average Recommendation of “Buy” by Brokerages

Share on StockTwits

Shares of DexCom, Inc. (NASDAQ:DXCM) have been assigned a consensus recommendation of “Buy” from the twenty-three analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have given a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $129.07.

A number of research analysts have recently commented on the stock. Morgan Stanley boosted their target price on shares of DexCom from $130.00 to $150.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 11th. Canaccord Genuity boosted their target price on shares of DexCom from $85.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, June 28th. BidaskClub cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st. Raymond James raised shares of DexCom from a “market perform” rating to an “outperform” rating in a research report on Monday, July 2nd. Finally, BMO Capital Markets boosted their target price on shares of DexCom to $112.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 10th.

In related news, EVP Andrew K. Balo sold 5,000 shares of DexCom stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $124.25, for a total value of $621,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Steven Robert Pacelli sold 3,114 shares of DexCom stock in a transaction on Wednesday, July 25th. The stock was sold at an average price of $101.91, for a total transaction of $317,347.74. The disclosure for this sale can be found here. In the last 90 days, insiders sold 191,104 shares of company stock valued at $25,638,120. Insiders own 1.80% of the company’s stock.

Large investors have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System increased its stake in DexCom by 0.4% during the second quarter. State Board of Administration of Florida Retirement System now owns 120,747 shares of the medical device company’s stock valued at $11,469,000 after purchasing an additional 470 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in DexCom by 9.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,552 shares of the medical device company’s stock valued at $527,000 after purchasing an additional 471 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in DexCom by 7.6% during the second quarter. Metropolitan Life Insurance Co. NY now owns 6,879 shares of the medical device company’s stock valued at $653,000 after purchasing an additional 486 shares during the last quarter. Xact Kapitalforvaltning AB increased its stake in DexCom by 4.1% during the second quarter. Xact Kapitalforvaltning AB now owns 12,700 shares of the medical device company’s stock valued at $1,206,000 after purchasing an additional 500 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in DexCom by 11.9% during the first quarter. PNC Financial Services Group Inc. now owns 5,943 shares of the medical device company’s stock valued at $440,000 after purchasing an additional 634 shares during the last quarter.

Shares of DXCM stock opened at $133.20 on Wednesday. DexCom has a fifty-two week low of $43.74 and a fifty-two week high of $148.56. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.62 and a current ratio of 4.89. The company has a market cap of $12.64 billion, a price-to-earnings ratio of -229.66 and a beta of 0.47.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, August 1st. The medical device company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.08. DexCom had a negative net margin of 0.65% and a negative return on equity of 7.45%. The business had revenue of $242.50 million for the quarter, compared to analysts’ expectations of $205.81 million. During the same period in the previous year, the company posted ($0.16) earnings per share. The business’s revenue for the quarter was up 42.1% compared to the same quarter last year. As a group, equities research analysts anticipate that DexCom will post -0.47 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: What are the Different Types of Leveraged Buyouts?

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply